[ET Net News Agency, 15 November 2019] BeiGene, Ltd. (06160) said that BRUKINSA
(zanubrutinib) has received accelerated approval from the United States Food and Drug
Administration (FDA) as a treatment for mantle cell lymphoma (MCL) in adult patients who
have received at least one prior therapy.
It said BRUKINSA is the first BeiGene-discovered product to be approved, an important
milestone toward the company's goal of transforming treatment for cancer patients around
the world. (KL)